Future criteria checks 4/6
Teva Pharmaceutical Industries is forecast to grow earnings and revenue by 47.3% and 2.2% per annum respectively. EPS is expected to grow by 43.5% per annum. Return on equity is forecast to be 25.2% in 3 years.
Key information
47.3%
Earnings growth rate
43.5%
EPS growth rate
| Pharmaceuticals earnings growth | 21.3% |
| Revenue growth rate | 2.2% |
| Future return on equity | 25.2% |
| Analyst coverage | Good |
| Last updated | 11 Mar 2024 |
Recent future growth updates
Recent updates
Teva And Alvotech: Simlandi Approval Opens New Generic Market Opportunities
Feb 26
A Review Of Teva's Prospects
Feb 15
Teva Pharmaceutical Industries Limited's (NYSE:TEVA) Business And Shares Still Trailing The Industry
Jan 07
These 4 Measures Indicate That Teva Pharmaceutical Industries (NYSE:TEVA) Is Using Debt In A Risky Way
Dec 11
Teva: 4 Key Drivers For A 2024 Revival (Upgraded Rating)
Dec 08
Teva: Deeply Undervalued FCF Machine
Nov 20
Teva: Focus On Innovation And Growth Means The Times They Are A Changing
Sep 14
Teva Pharmaceutical Industries (NYSE:TEVA) Has No Shortage Of Debt
Sep 09
The Mighty Teva Pharmaceutical: Unveiling A Bullish Scenario You Must Consider
Aug 26
Teva Q2 Earnings: Austedo And Anda Growth Impress, But Challenges Remain
Aug 02
Teva Pharmaceutical: Lacking Capabilities For Strategic Investments
Jul 20
Teva Pharmaceutical: New Growth Plan Could Restore Investor Confidence
Jun 15
Here's Why Teva Pharmaceutical Industries (NYSE:TEVA) Is Weighed Down By Its Debt Load
Jun 06
Is Teva Pharmaceutical Industries (NYSE:TEVA) A Risky Investment?
Feb 20
What To Expect From Teva Pharmaceutical In 2023 With A New CEO
Feb 15
Can Teva Pharmaceutical's Q4 results bring positive surprise?
Feb 07
Teva Pharmaceutical: Stuck In A Cycle Of Hope And Disappointment
Jan 19
Tamiflu supplies released from national stockpile as nationwide shortage persists
Jan 12
Teva Pharmaceutical: 2023 Could Finally Be The Stock's Breakout Year
Dec 28
Federal appeals court temporarily blocks generics of Vanda's Hetlioz by Teva, Apotex
Dec 16
Boston jury orders Lilly to pay $176.5M to Teva in migraine drug patent suit
Nov 10
Teva Pharmaceutical to pay New York $523M as part of opioid settlement
Nov 03
Teva data indicates long-term benefit of Austedo for chorea associated with Huntington's
Oct 18
Novartis division Sandoz reports supply issue of generic ADHD drug Adderall - Bloomberg
Oct 06
Teva Pharmaceutical: Slow And Steady Road To A Higher Share Price
Sep 28
Teva Pharmaceutical: Past Behind And A Promising 2023
Sep 16
Teva wins European approval for biosimilar to Roche’s eye therapy Lucentis
Aug 29
These 4 Measures Indicate That Teva Pharmaceutical Industries (NYSE:TEVA) Is Using Debt Extensively
Aug 05
Teva flags supply constraints to ADHD drug Adderall as demand rises - Bloomberg
Aug 03
Forex volatility, performance of generic drugs, opioid settlements in focus for Teva's Q2 earnings
Jul 26
Teva again in the sights of New York Attorney General over alleged role in opioid crisis
Jul 11
Teva names new medical chief
Jul 01
Teva Pharma Trends Lower Ahead Of A Key Shareholder Meeting This Week
Jun 20
3 Reasons To Buy Teva At $10
Apr 07
Does Teva Pharmaceutical Industries (NYSE:TEVA) Have A Healthy Balance Sheet?
Mar 24
Teva Pharmaceutical: Prepare For Takeoff
Feb 16
Teva: Competent Management Despite Lawsuits And Debts
Jan 28
Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | 16,736 | 1,383 | 2,715 | 1,475 | 9 |
| 12/31/2025 | 16,284 | 743 | 2,657 | 1,618 | 11 |
| 12/31/2024 | 15,855 | 420 | 2,678 | 872 | 10 |
| 12/31/2023 | 15,846 | -559 | 842 | 1,368 | N/A |
| 9/30/2023 | 15,273 | -2,209 | 608 | 1,157 | N/A |
| 6/30/2023 | 15,017 | -2,234 | 1,173 | 1,695 | N/A |
| 3/31/2023 | 14,925 | -1,603 | 964 | 1,494 | N/A |
| 12/31/2022 | 14,925 | -2,446 | 1,042 | 1,590 | N/A |
| 9/30/2022 | 15,141 | -1,291 | 514 | 1,073 | N/A |
| 6/30/2022 | 15,433 | -1,054 | 476 | 1,059 | N/A |
| 3/31/2022 | 15,557 | -615 | 585 | 1,154 | N/A |
| 12/31/2021 | 15,878 | 417 | 236 | 798 | N/A |
| 9/30/2021 | 16,231 | 726 | 88 | 673 | N/A |
| 6/30/2021 | 16,324 | -3,915 | -131 | 451 | N/A |
| 3/31/2021 | 16,284 | -3,982 | -94 | 506 | N/A |
| 12/31/2020 | 16,659 | -3,990 | 638 | 1,216 | N/A |
| 9/30/2020 | 16,673 | -4,031 | 902 | 1,423 | N/A |
| 6/30/2020 | 16,788 | 4 | 894 | 1,441 | N/A |
| 3/31/2020 | 17,095 | -825 | 413 | 941 | N/A |
| 12/31/2019 | 16,887 | -999 | 223 | 748 | N/A |
| 9/30/2019 | 16,396 | -4,048 | -42 | 577 | N/A |
| 6/30/2019 | 16,831 | -4,007 | 84 | 673 | N/A |
| 3/31/2019 | 17,355 | -3,559 | 449 | 1,062 | N/A |
| 12/31/2018 | 18,271 | -2,399 | 1,795 | 2,446 | N/A |
| 9/30/2018 | 19,693 | -11,059 | 2,233 | 2,938 | N/A |
| 6/30/2018 | 20,781 | -10,256 | 2,534 | 3,312 | N/A |
| 3/31/2018 | 21,800 | -16,050 | 2,750 | 3,585 | N/A |
| 12/31/2017 | 21,853 | -16,525 | 1,351 | 2,225 | N/A |
| 9/30/2017 | 23,479 | -5,963 | N/A | 2,791 | N/A |
| 6/30/2017 | 23,425 | -6,145 | N/A | 3,457 | N/A |
| 3/31/2017 | 22,743 | 78 | N/A | 3,985 | N/A |
| 12/31/2016 | 21,903 | 68 | N/A | 3,890 | N/A |
| 9/30/2016 | 20,292 | 1,591 | N/A | 5,415 | N/A |
| 6/30/2016 | 19,552 | 1,346 | N/A | 5,047 | N/A |
| 3/31/2016 | 19,480 | 1,697 | N/A | 5,564 | N/A |
| 12/31/2015 | 19,652 | 1,573 | N/A | 5,542 | N/A |
| 9/30/2015 | 19,939 | 1,775 | N/A | 5,679 | N/A |
| 6/30/2015 | 20,174 | 2,548 | N/A | 6,010 | N/A |
| 3/31/2015 | 20,253 | 2,757 | N/A | 5,583 | N/A |
| 12/31/2014 | 20,272 | 3,055 | N/A | 5,127 | N/A |
| 9/30/2014 | 20,534 | 2,748 | N/A | 4,191 | N/A |
| 6/30/2014 | 20,535 | 2,583 | N/A | 3,211 | N/A |
| 3/31/2014 | 20,414 | 1,383 | N/A | 3,033 | N/A |
| 12/31/2013 | 20,314 | 1,269 | N/A | 3,237 | N/A |
| 9/30/2013 | 20,133 | 1,209 | N/A | 3,998 | N/A |
| 6/30/2013 | 20,046 | 419 | N/A | 4,602 | N/A |
| 3/31/2013 | 20,116 | 1,734 | N/A | 4,918 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: TEVA is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2.3%).
Earnings vs Market: TEVA is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: TEVA is expected to become profitable in the next 3 years.
Revenue vs Market: TEVA's revenue (2.2% per year) is forecast to grow slower than the US market (8.1% per year).
High Growth Revenue: TEVA's revenue (2.2% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: TEVA's Return on Equity is forecast to be high in 3 years time (25.2%)
Discover growth companies
Price
7D
1Y
Mkt cap
PS
E.Growth
Analysts Target
Price
7D
1Y
Mkt cap
PS
E.Growth
Analysts Target
Price
7D
1Y
Mkt cap
PS
E.Growth
Analysts Target
Price
7D
1Y
Mkt cap
PS
E.Growth
Analysts Target
